Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 4, 2014, Pages 335-349

  Hu, Chuanpu ^a   Szapary, Philippe O ^a   Mendelsohn, Alan M ^a   Zhou, Honghui ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Discrete variable; Multivariate analysis; NONMEM; Population pharmacokinetic pharmacodynamic modeling; Psoriatic arthritis; Ustekinumab; Well controlled clinical trials

Indexed keywords

ALBUMIN; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; USTEKINUMAB; METHOTREXATE; MONOCLONAL ANTIBODY;

ANALYTICAL ERROR; ARTICLE; COMPARTMENT MODEL; CONCEPTUAL FRAMEWORK; EXPOSURE RESPONSE MODEL; EXTERNAL VALIDITY; HUMAN; INDIRECT RESPONSE JOINT MODEL; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION MODEL; PREDICTIVE VALUE; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOASSAY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; ENDPOINT DETERMINATION; HUMANS; INJECTIONS, SUBCUTANEOUS; METHOTREXATE; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS;

EID: 84906939573     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9366-0     Document Type: Article

References (19)

1. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21(4):457-478 (Pubitemid 24025269)
2. Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727-735
3. Hutmacher MM, Krishnaswami S, Kowalski KG (2008) Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn 35:139-157
4. Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE (2009) A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharm Therap 86(4):387-395.
5. Hu C, Xu Z, Rahman MU, Davis HM, Zhou H (2010) A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. J Pharmacokinet Pharmacodyn 37(4):309-321
6. Hu C, Xu Z, Mendelsohn A, Zhou H (2013) Latent variable indirect response modeling of categorical endpoints representing change from baseline. J Pharmacokinet Pharmacodyn 40(1):81-91
7. Hu C, Szapary PO, Yeilding N, Zhou H (2011) Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis. J Pharmacokinet Pharmacodyn 38(2):237-260
8. Hu C, Yeilding N, Davis HM, Zhou H (2011) Bounded outcome score modeling: application to treating psoriasis with ustekinumab. J Pharmacokinet Pharmacodyn 38(4):497-517
9. An X, Bentler PM (2011) Extended mixture factor analysis model with covariates for mixed binary and continuous responses. Stat Med 30:2634-2647
10. Laffont CM, Fink M, Gruet P, King JN, Seewald W, Concordet D (2012) Application of a new method for multivariate analysis of longitudinal ordinal data testing robenacoxib in canine osteoarthritis. PAGE 21 Abstr:2548
11. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM user's guides (1989-2009). Icon Development Solutions, Ellicott City
12. Hu C, Zhou H (2008) An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol 48:812-822 (Pubitemid 351871963)
13. Hu C, Zhang J, Zhou H (2011) Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat 10(7):812-822 (Pubitemid 351871963)
14. Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, Zhou H (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49(2):162-175
15. Zhang L, Beal S, Sheiner L (2003) Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 30:387-404 (Pubitemid 38221931)
16. Karlsson MO, Holford NHG (2008) A tutorial on visual predictive checks. PAGE 17:2008
17. Hutmacher MM, French JL, Krishnaswamib S, Menonb S (2011) Estimating transformations for repeated measures modeling of continuous bounded outcome data. Stat Med 30:935-949
18. Hu C, Sale M (2003) A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 30(1):83-103 (Pubitemid 36571070)
19. Woo S, Pawaskar D, Jusko WJ (2009) Methods of utilizing baseline values for indirect response models. J Pharmacokinet Pharmacodyn 36:381-405